Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern
Open accessThe DOI matches its Crossref record; 24 of the 27 references it cites were found in a registry or an index.
Abstract
Several reports showed that interleukin-6 (IL-6) or -8 (IL-8) might be useful inflammatory biomarkers for pancreatic ductal adenocarcinoma (PDAC), although these clinical impact is still open to debate. The aim of this study was to elucidate whether serum levels of IL-6 and IL-8 at diagnosis could predict the tumor progression pattern of PDAC, especially in extensive hepatic metastasis.According to the tumor burden of hepatic metastasis at the last follow-up, tumor progression pattern was defined as follows: no or limited (unilobar involvement and 5 or less in the within liver, limited group) and extensive hepatic metastasis (bilobar or more than 5, progressed group). Fifty-three PDAC patients with initially no or limited hepatic metastasis were enrolled retrospectively.Around 42 (79.2%) were included in the limited and 11 (20.8%) in the progressed group. The median serum level of IL-6 in the progressed group was elevated significantly compared with the limited group. However, the median serum level of IL-8 was not. Furthermore, multivariate analysis revealed that the elevated serum level of IL-6 was an independent risk factor for progression to extensive hepatic metastasis (odds ratio 1.928, 95% confidence interval 1.131-3.365, P = 0.019), but IL-8 was not. However, higher IL-6 did not predict shorter survival.High serum IL-6 can be an independent risk factor for progression to extensive hepatic metastasis in PDAC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that these ratios are reliable markers of inflammatory status, correlating well with other established inflammatory markers like C-reactive protein (CRP) and cytokine levels [22, 23].”
From Inflammatory ratios as predictors of length of hospitalization in psychiatric patients: A multicenter study (2025) · doi:10.1007/s00406-025-02033-9 · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
Fukuda, A., Wang, S. C., Morris, J. P., Folias, A. E., Liou, A., Kim, G. E., Akira, S., Boucher, K. M., Firpo, M. A., Mulvihill, S. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.002 · Cited by 521
Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis
Ebrahimi, B., Tucker, S. L., Li, D., Abbruzzese, J. L., & Kurzrock, R. (2004) · Cancer · doi:10.1002/cncr.20672 · Cited by 315
Roles of Pancreatic Stellate Cells in Pancreatic Inflammation and Fibrosis
Masamune, A., Watanabe, T., Kikuta, K., & Shimosegawa, T. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.038 · Cited by 271
Duell, E. J., Lucenteforte, E., Olson, S. H., Bracci, P. M., Li, D., Risch, H. A., Silverman, D. T., Ji, B. T., Gallinger, S., Holly, E. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds140 · Cited by 263 · cited 1×
“The crucial role of chronic inflammation in tumor development is particularly recognized in the context of pancreatic ductal adenocarcinoma (PDAC).([1,2]) Although the roles of interleukin-6 (IL-6) and interleukin-8 (IL-8) in cancer biology are still unclear, it has been suggested that IL-6 or IL-8 promote cell prolif…”
BackgroundInterleukin-6 in inflammatory and malignant diseases of the pancreas
Lesina, M., Wörmann, S. M., Neuhöfer, P., Song, L., & Algül, H. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.002 · Cited by 162
Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Furuse, J., Inagaki, M., Higashi, S., Kato, H., Terao, K., & Ochiai, A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.174 · Cited by 153
Cited by
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets
Unver, N., & McAllister, F. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.004 · Cited by 238
Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer
Geng, X., Chen, H., Zhao, L., Hu, J., Yang, W., Li, G., Cheng, C., Zhao, Z., Zhang, T., Li, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655152 · Cited by 185
“CAFs can secrete chemokines (Scherz-Shouval et al., 2014; Kumar et al., 2017) and cytokines (Biffi et al., 2019), which leads to lymphatic angiogenesis (Cadamuro et al., 2019) to promote cancer cell intravasation.”
BackgroundTsujikawa, T., Crocenzi, T. S., Durham, J. N., Sugar, E. A., Wu, A. A., Onners, B., Nauroth, J. M., Anders, R. A., Fertig, E. J., Laheru, D. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3978 · Cited by 172
Vainer, N., Dehlendorff, C., & Johansen, J. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25661 · Cited by 160
Metadata
- Authors
- Kim, H. W., Lee, J.-C., Paik, K.-H., Kang, J., Kim, J., & Hwang, J.-H.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Hwang, Jin-Hyeok
- Venue
- Medicine
- Published
- 2017-02
- Volume
- 96
- Issue
- 5
- Pages
- e5926
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC5293435
- OpenAlex
- W2617028083
- Cited by
- 52
- References
- 27
- Citations by year
- 2025: 5 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 10 · 2017: 1
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nd
- Locations
- Medicine (publishedVersion, cc-by-nd)
- PubMed Central (publishedVersion, cc-by-nd)
- PubMed (publishedVersion)
- Funders
- Seoul National University Bundang Hospital
- Seoul National University
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- pancreatic ductal adenocarcinoma, interleukin-6, interleukin-8, serum biomarkers, liver metastasis, tumor progression, inflammatory markers, prognostic factors, survival
- MeSH terms
- Aged, Female, Humans, Liver Neoplasms, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Retrospective Studies, Risk Factors, Biomarkers, Tumor, Interleukin-6, Interleukin-8, Disease Progression, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. https://app.cochat.ai/papers/10.1097/md.0000000000005926
- The paper
- Kim, H. W., Lee, J.-C., Paik, K.-H., Kang, J., Kim, J., & Hwang, J.-H. (2017). Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine. https://doi.org/10.1097/md.0000000000005926
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.